Actively Recruiting

Age: 18Years +
All Genders
ID04629677

Prospective Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Malignancies

Led by M.D. Anderson Cancer Center · Updated on 2026-01-12

150

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

M

M.D. Anderson Cancer Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effects of portal vein stenting in patients with gastrointestinal cancers who have narrowing of the portal vein. The study aims to learn how long the portal vein remains open and free from blockage after stenting, and how this procedure affects patients' overall well-being and quality of life. It compares patients who receive the stenting procedure with those who do not undergo stenting. Patients are divided into two groups. Cohort A includes patients who receive portal vein stenting and complete quality of life questionnaires at 2-4 weeks and again at 6-8 weeks after the procedure, with their medical records reviewed. Cohort B includes patients with portal vein narrowing or thrombosis who did not receive stenting, and only their medical records are reviewed retrospectively. Participants in Cohort A will have their quality of life, liver function, liver volume, nutritional status, bleeding risk, transfusion needs, and ascites management monitored up to 8 weeks after stenting. Both cohorts will have medical records reviewed for these outcomes. This study is observational, focusing on collecting data and assessing outcomes related to the portal vein stenting procedure and its effects on patients with gastrointestinal cancer and portal vein stenosis.

CONDITIONS

Brief Title

Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must be 18 years or older.
  • Patients with gastrointestinal cancer undergoing standard staging and treatment.
  • Patients with more than 75% narrowing in the main portal vein, left portal vein, right portal vein, or superior mesenteric vein, regardless of symptoms.
  • Patients with any degree of vascular narrowing and symptoms of portal hypertension such as variceal bleeding, refractory ascites, abdominal pain, intestinal swelling, or diarrhea after ruling out tumor invasion or spread.
  • For Cohort B, patients with thrombosis or narrowing of the main portal vein who did not have stenting.
Not Eligible

You will not qualify if you...

  • Patients with vascular narrowing caused directly by tumor invasion or peritoneal spread.
  • Patients who do not meet the age requirement of being 18 years or older.
  • Patients without portal vein stenosis or thrombosis.
  • Patients who have undergone portal vein stenting prior to the study (for Cohort B).
  • Patients unable to complete quality of life questionnaires or medical record review as required for Cohort A or B respectively, if applicable.
  • Patients with other medical conditions that may interfere with study participation or outcomes, as determined by the investigator (implied).

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for eligibility assessment and consent

Implementation

Duration - Up to 8 weeks after stent placement

Participants in Cohort A undergo portal vein stenting and complete quality of life questionnaires at 2 to 4 weeks and 6 to 8 weeks after the procedure. Medical records are reviewed for both cohorts.

2 visits for questionnaire completion in Cohort A; medical record reviews for all participants

Long-term Monitoring

Duration - Up to 8 weeks post procedure

Participants' medical records are reviewed retrospectively to evaluate clinical outcomes such as transfusion rates, liver function, and nutritional status.

No additional visits; medical record review only

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

J

Joshua D. Kuban

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Phase II Evaluation of 2 Versus 6 Hour Oxaliplatin Infusions...

Malignant Digestive System Neoplasm

Actively Recruiting

3 locations

Data Collection to Assess Acute and Late Normal Tissue Seque...

Breast Carcinoma

Actively Recruiting

1 location

Fucoidan for Patients With Chemotherapy-Related Fatigue: A D...

Malignant Digestive System Neoplasm

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here